| |
property for sale in balchik varna brovets bansko bulgaria
News and Information Article
Phillip Singerman, PhD, to Help Drive Development of Life Science and
Technology Companies
BETHESDA, Md., Jan. 18 // -- Toucan Capital today announced the
appointment of Phillip Singerman, Ph.D. as a new Venture Partner. Singerman
most recently served as the founding Executive Director of the Maryland
Technology Development Corporation (TEDCO), a State-sponsored technology
transfer and commercialization agency. During his six-year tenure, TEDCO
garnered a national reputation for successfully investing public funds in
technology start-ups. Singerman also guided technology transfer from federal
laboratories and state universities to the commercial market. Entrepreneur
Magazine named TEDCO "the most active seed fund investor in the nation" in
2003 and 2004.
Linda Powers, Co-Founder and Managing Director of Toucan Capital Fund II
L.P., stated, "Dr. Singermans long experience in seed funding and development
of early-stage companies, as well as commercialization of emerging
technologies, will greatly benefit our portfolio companies. He is a proven
investor and entrepreneur, with a record of successful investments and
building enduring organizations. We look forward to extensive contributions
from him in growing the life science and technology companies in our
portfolio."
Dr. Singerman commented, "I am delighted to be joining Toucan Capitals
management team. I have worked with the venture capital community for over
two decades, and I feel Toucan is unique because of its focus on early-stage
investing and building companies around emerging technologies. I look forward
to utilizing my experience to help Toucans companies get to the next level in
their commercialization efforts."
Prior to joining TEDCO, Singerman served as U.S. Assistant Secretary of
Commerce for Economic Development in the Clinton Administration, and also as
President and CEO of the Ben Franklin Technology Center of Southeastern
Pennsylvania. Singerman holds a Ph.D. from Yale University and a B.A. from
Oberlin College, and served as a Peace Corps Volunteer in Colombia.
Toucan Capital, a $120 million venture capital fund based in Bethesda,
Maryland, invests nationwide and is especially active in the mid-Atlantic
region, one of the richest markets in the country for life sciences and
certain advanced technologies, and a market generally underserved by venture
capital. Toucan often serves as the lead or co-lead investor and takes an
active, hands-on role working closely with company management to help build
its portfolio companies. Toucan helps its companies in building and
strengthening their intellectual property base, formulating partnering and
regulatory strategies, and addressing commercialization and
payment/reimbursement issues from the earliest stages of the companys
development.
Toucans life sciences portfolio includes extensive investments in stem
cells and tissue engineering, biologics and immunotherapies, as well as small
molecule drugs and medical devices. Toucans non-life science portfolio
includes nanotechnology and certain other advanced technologies. Portfolio
companies in the Metro Washington DC area include Cognate Therapeutics, RNT,
and Trophogen. For further information please visit the Toucan website at
http://www.toucancapital.com.
Statements made in this news release that are not historical facts are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Words such as "expects," "believes,"
"intends," and similar expressions are intended to identify forward-looking
statements. Actual results may differ materially from those projected in any
forward-looking statement. The Company assumes no obligation to update any
forward-looking statements as a result of new information, future events or
developments, except as required by securities laws.
| |
|
|
 |
property for sale in balchik varna brovets bansko bulgaria |
|
|
|
|
|
|
|
|
|
Locations
